Vaxcyte (NASDAQ:PCVX) Shares Unloaded Rep. Jefferson Shreve

Representative Jefferson Shreve (R-Indiana) recently sold shares of Vaxcyte, Inc. (NASDAQ:PCVX). In a filing disclosed on April 11th, the Representative disclosed that they had sold between $15,001 and $50,000 in Vaxcyte stock on March 5th. The trade occurred in the Representative’s “CRT – STANDARD UNIT TRUST” account.

Representative Jefferson Shreve also recently made the following trade(s):

• Purchased $15,001 – $50,000 in shares of Harley-Davidson (NYSE:HOG) on 3/31/2025.
• Purchased $50,001 – $100,000 in shares of Block (NYSE:XYZ) on 3/31/2025.
• Sold $15,001 – $50,000 in shares of DuPont de Nemours (NYSE:DD) on 3/31/2025.
• Purchased $15,001 – $50,000 in shares of United Community Banks (NASDAQ:UCB) on 3/31/2025.
• Sold $15,001 – $50,000 in shares of IDEX (NYSE:IEX) on 3/31/2025.
• Purchased $15,001 – $50,000 in shares of HNI (NYSE:HNI) on 3/31/2025.
• Sold $50,001 – $100,000 in shares of ServiceNow (NYSE:NOW) on 3/31/2025.
• Sold $15,001 – $50,000 in shares of Coinbase Global (NASDAQ:COIN) on 3/31/2025.
• Sold $15,001 – $50,000 in shares of Constellation Energy (NASDAQ:CEG) on 3/31/2025.
• Sold $50,001 – $100,000 in shares of Simon Property Group (NYSE:SPG) on 3/31/2025.

Vaxcyte Price Performance

Shares of PCVX opened at $32.04 on Tuesday. The company has a 50-day moving average of $65.25 and a two-hundred day moving average of $84.98. The stock has a market cap of $4.13 billion, a price-to-earnings ratio of -6.97 and a beta of 1.26. Vaxcyte, Inc. has a one year low of $27.66 and a one year high of $121.06.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($1.02) EPS for the quarter, topping analysts’ consensus estimates of ($1.16) by $0.14. Analysts anticipate that Vaxcyte, Inc. will post -4.21 earnings per share for the current year.

Institutional Trading of Vaxcyte

Several large investors have recently made changes to their positions in PCVX. Whipplewood Advisors LLC acquired a new stake in Vaxcyte in the 4th quarter worth approximately $28,000. Smartleaf Asset Management LLC lifted its stake in shares of Vaxcyte by 188.4% in the fourth quarter. Smartleaf Asset Management LLC now owns 398 shares of the company’s stock worth $33,000 after buying an additional 260 shares during the last quarter. National Bank of Canada FI bought a new stake in shares of Vaxcyte during the 4th quarter worth $41,000. Blue Trust Inc. grew its stake in Vaxcyte by 100.0% in the 4th quarter. Blue Trust Inc. now owns 742 shares of the company’s stock valued at $61,000 after buying an additional 371 shares during the last quarter. Finally, Parallel Advisors LLC raised its holdings in Vaxcyte by 203.6% in the 1st quarter. Parallel Advisors LLC now owns 1,597 shares of the company’s stock worth $61,000 after acquiring an additional 1,071 shares during the period. Institutional investors own 96.78% of the company’s stock.

Insiders Place Their Bets

In other Vaxcyte news, Director Teri Loxam sold 6,250 shares of the firm’s stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $85.11, for a total value of $531,937.50. Following the sale, the director now directly owns 7,175 shares in the company, valued at $610,664.25. This trade represents a 46.55 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Andrew Guggenhime sold 8,000 shares of the company’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $86.51, for a total transaction of $692,080.00. Following the transaction, the chief financial officer now directly owns 109,491 shares of the company’s stock, valued at $9,472,066.41. This represents a 6.81 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 38,250 shares of company stock valued at $3,170,738 in the last quarter. Insiders own 3.10% of the company’s stock.

Wall Street Analyst Weigh In

PCVX has been the topic of several recent analyst reports. Evercore ISI raised Vaxcyte to a “strong-buy” rating in a research report on Monday, March 31st. The Goldman Sachs Group dropped their price target on shares of Vaxcyte from $138.00 to $100.00 and set a “buy” rating on the stock in a research note on Tuesday, April 1st. Needham & Company LLC reissued a “buy” rating and set a $90.00 price objective on shares of Vaxcyte in a research report on Tuesday, April 8th. Guggenheim reaffirmed a “buy” rating and issued a $160.00 target price on shares of Vaxcyte in a research report on Wednesday, March 12th. Finally, Bank of America reduced their price target on Vaxcyte from $157.00 to $137.00 and set a “buy” rating for the company in a report on Tuesday, April 1st. Nine equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Vaxcyte presently has an average rating of “Buy” and a consensus price target of $136.50.

About Representative Shreve

Jefferson Shreve (Republican Party) is a member of the U.S. House, representing Indiana’s 6th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Shreve (Republican Party) is running for re-election to the U.S. House to represent Indiana’s 6th Congressional District. He declared candidacy for the 2026 election.

Email [email protected] to notify us of updates to this biography.
Jefferson Shreve earned a bachelor’s degree from Indiana University in 1989, a graduate degree from the University of London in 1998, and a graduate degree from Purdue University in 2003. Shreve’s career experience includes working as a real estate executive.

Shreve was elected 7th District Vice Chairman of the Indiana Republican State Committee on January 17, 2018, and was re-elected on March 6, 2021. In 2020, he was selected as a district-level delegate to the 2020 Republican National Convention.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.